M. Hebron

发表

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Raymond Scott Turner, P. Aisen, R. Turner, 2017, Journal of Neuroinflammation.

Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

C. Moussa, Monica Javidnia, M. Hebron, 2017, Journal of Alzheimer's disease : JAD.

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease

Jaeil Ahn, C. Moussa, M. Hebron, 2019, JAMA neurology.

Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer's Disease.

C. Moussa, M. Hebron, Wangke Shi, 2019, Journal of Alzheimer's disease : JAD.

Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies

C. Moussa, M. Hebron, I. Lonskaya, 2018, Human molecular genetics.

Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance

C. Moussa, M. Hebron, Nicole M. Desforges, 2013, PloS one.

Nilotinib reverses loss of dopamine neurons and improvesmotorbehaviorviaautophagicdegradation

C. Moussa, M. Hebron, I. Lonskaya, 2013 .

Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson’s disease

C. Moussa, M. Hebron, Nicole M. Desforges, 2013, Neuroscience.

Parkin prevents cortical atrophy and A β -induced alterations of brain metabolism: 13 C NMR and MRI studies in AD models

C. Moussa, M. Hebron, N. Algarzae, 2012 .

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease

Jaeil Ahn, S. Schwartz, C. Moussa, 2019, Pharmacology research & perspectives.

Tyrosine kinase inhibition facilitates autophagic SNCA/α-synuclein clearance

C. Moussa, M. Hebron, I. Lonskaya, 2013, Autophagy.

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

Jaeil Ahn, C. Moussa, M. Hebron, 2022, Alzheimer's & dementia.

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models

C. Moussa, M. Hebron, J. Schachter, 2014, Molecular Neurodegeneration.

Tyrosine kinase inhibition reverses TDP‐43 effects on synaptic protein expression, astrocytic function and amino acid dis‐homeostasis

Charisse N. Winston, Z. Li, C. Moussa, 2016, Journal of neurochemistry.

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration

C. Moussa, M. Hebron, 2015, Neural regeneration research.

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease

C. Moussa, Jaeil Ahn, M. Hebron, 2020, Movement disorders : official journal of the Movement Disorder Society.

Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice

C. Moussa, K. Balaraman, M. Hebron, 2022, International journal of molecular sciences.

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology

K. Balaraman, C. Moussa, M. Hebron, 2021, Metabolites.

metabolites Novel Ubiquitin Speciﬁc Protease-13 Inhibitors Alleviate Neurodegenerative Pathology

C. Moussa, K. Balaraman, M. Hebron, 2021 .

Label-free affinity screening, design and synthesis of inhibitors targeting the Mycobacterium tuberculosis L-alanine dehydrogenase

C. Strauss, Ruilian Wu, T. Terwilliger, 2022, PloS one.

Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models

Raymond Scott Turner, R. Turner, C. Moussa, 2015, Neuroscience.

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy

C. Moussa, M. Hebron, S. Selby, 2014, Journal of clinical & cellular immunology.

Parkin prevents cortical atrophy and Aβ-induced alterations of brain metabolism: 13C NMR and magnetic resonance imaging studies in AD models

C. Moussa, M. Hebron, M. Miessau, 2012, Neuroscience.

Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models

C. Moussa, M. Hebron, I. Lonskaya, 2017, Journal of Neuroimmunology.

Parkin reverses TDP‐43‐induced cell death and failure of amino acid homeostasis

C. Moussa, M. Hebron, Wenqiang Chen, 2014, Journal of neurochemistry.

Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice.

J. Neale, C. Moussa, M. Hebron, 2014, Human molecular genetics.

Parkin Ubiquitinates Tar-DNA Binding Protein-43 (TDP-43) and Promotes Its Cytosolic Accumulation via Interaction with Histone Deacetylase 6 (HDAC6)*

C. Moussa, M. Hebron, I. Lonskaya, 2012, The Journal of Biological Chemistry.

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients

C. Moussa, R. Varghese, M. Hebron, 2022, Metabolites.

CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease

H. Ressom, Jaeil Ahn, C. Moussa, 2021, Neurology: Genetics.

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

C. Moussa, M. Hebron, Charbel E-H Moussa, 2013, Human molecular genetics.

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Jaeil Ahn, Jaeil Ahn, S. Rogers, 2016, Journal of Parkinson's disease.

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models

C. Moussa, M. Hebron, J. Schachter, 2014, Molecular Neurodegeneration.

Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models

C. Moussa, M. Hebron, I. Lonskaya, 2014, Experimental Neurology.

Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.

H. Ressom, Jaeil Ahn, C. Moussa, 2020, Human molecular genetics.

Diminished parkin solubility and co-localization with intraneuronal amyloid-β are associated with autophagic defects in Alzheimer's disease.

C. Moussa, M. Hebron, Nicole M. Desforges, 2012, Journal of Alzheimer's disease : JAD.

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration

C. Moussa, M. Hebron, Xiaokong Gao, 2019, Drugs in R&D.

Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases

C. Moussa, M. Hebron, Nicole M. Desforges, 2012, International journal of Alzheimer's disease.

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance

C. Moussa, M. Hebron, J. Schachter, 2013, Journal of Molecular Medicine.

Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance

C. Moussa, M. Hebron, Nicole M. Desforges, 2013, EMBO molecular medicine.

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease

Raymond Scott Turner, Xiong Jiang, G. Esposito, 2020, Annals of neurology.

Tau clearance improves astrocytic function and brain glutamate-glutamine cycle

C. Moussa, M. Hebron, M. Javidnia, 2018, Journal of the Neurological Sciences.

Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance

C. Moussa, M. Hebron, J. Schachter, 2014, Journal of Molecular Medicine.

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

Raymond Scott Turner, R. Varghese, C. Moussa, 2023, Journal of Neuroinflammation.

Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.

H. Ressom, Jaeil Ahn, C. Moussa, 2021, Human molecular genetics.

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

C. Moussa, M. Hebron, I. Lonskaya, 2013, Human molecular genetics.